UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
October 31, 2007
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
711
Executive Blvd., Suite Q
Valley
Cottage, New York 10989
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F x Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
x
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
Incorporation
by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated October 31,
2007 is hereby incorporated by reference into the registration statements on
Form F-3 (File No. 333-141529 and File No. 333-147024) filed by XTL
Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March
23,
2007 and October 30, 2007, respectively.
XTL
Announces Delisting from the Official List of the United Kingdom Listing
Authority
Processing
Fees on Transfer of Ordinary Shares into ADRs to be Waived for An Additional
Month
Valley
Cottage, New York, October 31, 2007 -
XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTL) today announced that the
Company's ordinary shares have been delisted from the Official List of the
United Kingdom Listing Authority, pursuant to the October 2, 2007 vote at the
Company’s Extraordinary General Meeting. With the cancellation of the listing on
the London Stock Exchange, shareholders may deposit their ordinary shares with
the Company’s depositary bank, The Bank of New York, in exchange for American
Depositary Receipts, or ADRs, which are traded on NASDAQ, or trade their
ordinary shares on the TASE.
XTL
Biopharmaceuticals Ltd. has further announced that issuances of ADRs by The
Bank
of New York will be processed free of the customary charges of The Bank of
New
York for an additional month, through November 30, 2007. The Bank of New York
will issue ADRs representing American Depositary Shares, or ADSs, if
shareholders or their broker deposit Ordinary Shares with The Bank of New York’s
Custodian, either the Tel Aviv office of Bank Hapoalim B.M., or the London
office of The Bank of New York. One ADR will represent an ownership interest
in
ten of the Company’s Ordinary Shares.
Interested
investors should contact their brokers to discuss the waived fee and, should
they have any questions, can contact The Bank of New York in either London
or
New York as follows:
|
London
|
or
|
New
York
|
|
Mark
Lewis
|
Jason
Paltrowitz
|
|
|
Vice
President
|
Vice
President
|
|
|
Tel
020.7964.6089
|
Tel
212.815.2077
|
|
|
Fax
020.7964.6024
|
Fax
212.815.3004
|
|
|
marlewis@bankofny.com
|
jpaltrowitz@bankofny.com
|
|
ABOUT
XTL BIOPHARMACEUTICALS LTD.
XTL
Biopharmaceuticals Ltd. (“XTL”) is engaged in the development of therapeutics
for the treatment of neuropathic pain and hepatitis C. XTL is developing
Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment
of diabetic neuropathic pain. XTL is also developing several novel pre-clinical
hepatitis C small molecule inhibitors. XTL also has an active in-licensing
and
acquisition program designed to identify and acquire additional drug candidates.
XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (NASDAQ:
XTLB;
TASE: XTL).
Contact:
Ron
Bentsur, Chief Executive Officer
Tel:
+1-(845)-267-0707 ext. 225
Cautionary
Statement
Some
of the statements included in this press release, particularly those
anticipating continued undisrupted trading of the Company’s ADRs on NASDAQ and
similar matters, may be forward-looking statements that involve a number of
risks and uncertainties. For those statements, we claim the protection of the
safe harbor for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. Risk factors that could adversely affect our
operations are identified from time to time in our reports filed with the
Securities and Exchange Commission, including our annual report on Form 20-F
filed with the Securities and Exchange Commission on March 23, 2007. Any
forward-looking statements set forth in this press release speak only as of
the
date of this press release. We do not intend to update any of these
forward-looking statements to reflect events or circumstances that occur after
the date hereof. This press release and prior releases are available at
http://www.xtlbio.com. The information in our website is not incorporated by
reference into this press release and is included as an inactive textual
reference only. This press release is for informational purposes only and is
not
an offer to by or the solicitation of an offer to sell any
securities.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| XTL BIOPHARMACEUTICALS LTD. | ||
| |
|
|
| Date: October 31, 2007 | By: | /s/ Ron Bentsur |
|
Ron Bentsur |
||
|
Chief
Executive Officer
|
||